NCT05191875View on ClinicalTrials.gov

Saccharomyces Boulardii as Pretreatment Before Rescue Therapy of Helicobacter Pylori

NACompletedINTERVENTIONAL
Enrollment

106

Participants

Timeline

Start Date

December 1, 2021

Primary Completion Date

April 12, 2022

Study Completion Date

April 23, 2022

Conditions
Helicobacter Pylori Infection
Interventions
DRUG

Saccharomyces Boulardii 250 MG

"Saccharomyces Boulardii:~0.25 g \* 6, Produced by The French encyclopedia pharmaceutical Factory"

DRUG

Ilaprazole.Doxycycline. Furazolidone. Colloidal Bismuth Tartrate

"Ilaprazole:~5mg\*6, produced by Livzon Pharmaceutical Group Inc~Doxycycline:~0.1 g \* 10, produced by Jiangsu Yongxin Ltd.~Furazolidone:~0.1g\*100 produced by Tianjin Lisheng Pharmaceutical Co., LTD~Colloidal Bismuth Tartrate:~55 mg \* 36,produced by Shanxi Xinbaoyuan Pharmaceutical Co., LTD"

Trial Locations (1)

410013

The Third Xiangya Hospital of Central South University, Changsha

All Listed Sponsors
lead

The Third Xiangya Hospital of Central South University

OTHER

NCT05191875 - Saccharomyces Boulardii as Pretreatment Before Rescue Therapy of Helicobacter Pylori | Biotech Hunter | Biotech Hunter